<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02654236</url>
  </required_header>
  <id_info>
    <org_study_id>TREAT 005</org_study_id>
    <nct_id>NCT02654236</nct_id>
  </id_info>
  <brief_title>Effect of Heavy Alcohol Consumption on Farnesoid X Receptor (FXR) Signaling</brief_title>
  <official_title>Effect of Heavy Alcohol Consumption on Farnesoid X Receptor (FXR) Signaling</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suthat Liangpunsakul</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Intercept Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to see whether heavy drinking will interfere with a
      specific pathway, called FXR signaling in the liver. The abnormality of this pathway may lead
      to liver injury in some patients who drink heavily.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure change in bile salt metabolism (C4 )levels to determine effect of FXR</measure>
    <time_frame>Baseline to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure change in FGF19 levels to determine effect of FXR</measure>
    <time_frame>Baseline to 28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure change in fasting serum bile salt levels</measure>
    <time_frame>Baseline to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine change in oxidative stress level by measuring malondialdehyde and 8-isoprostane</measure>
    <time_frame>Baseline to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine change in CYP2E1 activity by measuring chlorzoxazone clearance</measure>
    <time_frame>Baseline to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine change in gut permeability through lactulose/mannitol test</measure>
    <time_frame>Baseline to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine change in bacterial translocation through measures of plasma LPS and serum sCD14</measure>
    <time_frame>Baseline to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine change in intestinal inflammation by measuring stool calprotectin</measure>
    <time_frame>Baseline to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine change in activation of innate immunity through measures of TNF-alpha, IL-1, IL-6 and IL-8</measure>
    <time_frame>Baseline to 28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Alcohol Consumption</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Heavy Drinkers on placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg Obeticholic Acid (OCA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-drinking Controls</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Non-drinking healthy controls</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 tablet of placebo, taken orally daily with water, approximately 30 minutes prior to breakfast for 4 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10 mg Obeticholic Acid (OCA)</intervention_name>
    <description>10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily, approximately 30 minutes prior to breakfast for 4 weeks.</description>
    <arm_group_label>10 mg Obeticholic Acid (OCA)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals â‰¥ 21 to 65 years old

          -  Able to provide informed consent &amp; negative urine pregnancy test where appropriate

          -  Healthy controls must have not consumed any alcohol within 3 months prior to the
             screening visit

          -  Heavy alcohol drinking is defined as &gt; 40 grams per day on average in women and &gt; 60
             grams per day on average in men for a minimum of 6 months

          -  Women of child bearing potential should be willing to practice contraception
             throughout the treatment period

        Exclusion Criteria:

          -  Active infection as evidenced by positive urine culture, blood culture, or pneumonia

          -  Serum creatinine &gt; 1.5 mg/dL

          -  Known co-existing infection with hepatitis C, hepatitis B, or HIV

          -  Significant systemic or major illness including COPD, CHF and renal failure that in
             the opinion of the Investigator would preclude the patient from participating in and
             completing the study.

          -  Participation in another investigational drug, biologic, or medical device trial
             within 30 days prior to Screening

          -  Previous history of jaundice or signs of liver diseases such as spider angiomata,
             ascites, or history of esophageal varices or hepatic encephalopathy

          -  Total bilirubin &gt; 2 mg/dl and INR &gt; 1.5 Page 20 of 37

          -  Women who are pregnant or nursing

          -  Presence of any other disease or condition that is interfering with the absorption,
             distribution, metabolism, or excretion of drugs including bile salt metabolism in the
             intestine. Patients who have undergone gastric bypass procedures will be excluded
             (gastric lap band is acceptable).

          -  Subjects who are taking warfarin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suthat Liangpunsakul, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Lehman, RN</last_name>
    <phone>(317) 278-1872</phone>
    <email>jgeck@iu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Megan Comerford, BS, MPH</last_name>
    <phone>3172789226</phone>
    <email>mcomerfo@iu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Lehman, RN</last_name>
      <phone>317-278-1872</phone>
      <email>jgeck@iu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Megan Comerford, BS, MPH</last_name>
      <phone>3172789226</phone>
      <email>mcomerfo@iu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Naga Chalasani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Suthat Liangpunsakul, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Crabb, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2016</study_first_submitted>
  <study_first_submitted_qc>January 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2016</study_first_posted>
  <last_update_submitted>February 21, 2018</last_update_submitted>
  <last_update_submitted_qc>February 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University School of Medicine</investigator_affiliation>
    <investigator_full_name>Suthat Liangpunsakul</investigator_full_name>
    <investigator_title>Suthat Liangpunsakul, Associate Professor of Medicine, Biochemistry and Molecular Biology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chenodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

